• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MDC
Click for more information
0.00% $6.60

MEDLAB CLINICAL LIMITED - Announcements

Market Cap $15.07M  ! watchlist Created with Sketch. Add to my watchlist

Medlab Clinical Limited (Medlab) is an Australia-based biotechnology company focused on... Medlab Clinical Limited (Medlab) is an Australia-based biotechnology company focused on the development and commercialization of a pharmaceutical delivery platform. The Company is investigating a range of prescription and non-prescription solutions for unmet patient needs across a variety of therapeutic areas, including pain management, mental health, gut health, diabetes, and allergies. The Company’s drug candidates include NanaBis, NanoCBD and NanoCelle. Medlab’s pipeline comprises a range of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. The Company's lead drug candidate, NanaBis, is under development for cancer bone pain as an alternative to opioid use and NanoCBD for mental stress . The Company also has a drug delivery platform called NanoCelle, which is wholly owned by Medlab and developed in Medlab’s owned Office of the Gene Technology Regulator (OGTR) registered laboratory.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
MDC NanaBis UpdatePRICE SENSITIVE14/03/19
MDC Cleansing Statement & Appendix 3B08/03/19
MDC S&P DJI Announces March 2019 Quarterly RebalancePRICE SENSITIVE08/03/19
MDC MDC Executes HoA for NanaBis with Pharmascience IncPRICE SENSITIVE05/03/19
MDC Half Year Accounts22/02/19
MDC Appendix 4DPRICE SENSITIVE22/02/19
MDC MDC's Depression Trial ExpandsPRICE SENSITIVE14/02/19
MDC Appendix 4C - quarterlyPRICE SENSITIVE30/01/19
MDC Medlab to Expand Nutraceutical Range into 2,100 PharmaciesPRICE SENSITIVE30/01/19
MDC MDC Receives formal SME Qualification from EMAPRICE SENSITIVE17/01/19
MDC NanoStat Demonstrates Improvement When Compared to Oral DrugPRICE SENSITIVE09/01/19
MDC Medlab - Open Day05/12/18
MDC Medlab Expands into EuropePRICE SENSITIVE04/12/18
MDC Change in substantial holding05/11/18
MDC Change in substantial holding30/10/18
MDC Successful Completion of Stage 1 of NanaBis TrialPRICE SENSITIVE30/10/18
MDC Results of Meeting26/10/18
MDC Appendix 4C - quarterlyPRICE SENSITIVE26/10/18
MDC AGM Presentation 201826/10/18
MDC Notice of Annual General Meeting/Proxy Form24/09/18
MDC Medlab Granted a Licence to Export CannabisPRICE SENSITIVE11/09/18
MDC Independent Research Validates Science around NanoCellePRICE SENSITIVE04/09/18
MDC Corporate Governance Statement 201831/08/18
MDC Appendix 4G31/08/18
MDC Annual Report to shareholders31/08/18
MDC Preliminary Final ReportPRICE SENSITIVE31/08/18
MDC Medlab Expands in Significant Area of Oncology with TrialPRICE SENSITIVE27/08/18
MDC Change in substantial holding17/08/18
MDC Appendix 4C - quarterlyPRICE SENSITIVE31/07/18
MDC Aphria Completes Largest Export Shipment to Date to MedlabPRICE SENSITIVE27/07/18 download Created with Sketch. 817.9KB
MDC Recruitment Begins - Phase 2A Trial for Depression MedicinePRICE SENSITIVE25/07/18 download Created with Sketch. 249.68KB
MDC Pain Trial on Schedule and Initial Doctor Feedback PositivePRICE SENSITIVE04/07/18 download Created with Sketch. 996.81KB
MDC MDC Cannabis Shipment Complated and Trial CommencementPRICE SENSITIVE15/05/18
MDC Appendix 3Y01/05/18
MDC Appendix 4C - quarterlyPRICE SENSITIVE30/04/18
MDC Letter to Shareholders23/04/18
MDC Ceasing to be a substantial holder from MUFG04/04/18
MDC Ceasing to be a substantial holder from MS04/04/18
MDC Becoming a substantial holder from MUFG29/03/18
MDC Becoming a substantial holder from MS28/03/18
MDC S&P DJ Indices Announces March Quarterly RebalancePRICE SENSITIVE09/03/18
MDC Medlab's Progress to Date on Cannabis Spray (NanaBis)PRICE SENSITIVE02/03/18
MDC Appendix 4DPRICE SENSITIVE28/02/18
MDC Half Year Accounts28/02/18
MDC Change in substantial holding05/02/18
MDC Change in substantial holding05/02/18
MDC Change in substantial holding05/02/18
MDC Appendix 3B and Notice under Section 708(5)(e)01/02/18
MDC Medlab Permitted to Sell or Supply Cannabis in QLD and ACTPRICE SENSITIVE01/02/18
MDC Appendix 4C - quarterlyPRICE SENSITIVE31/01/18
MDC Successful Completion of a Heavily Over-Subscribed PlacementPRICE SENSITIVE25/01/18
MDC Trading HaltPRICE SENSITIVE23/01/18
MDC Medlab Granted Licences-Sell or Supply Cannabis in AustraliaPRICE SENSITIVE10/01/18
MDC MDC's Cannabis (CBD/THC) Product expected Late Feb 18PRICE SENSITIVE23/11/17
MDC Change in substantial holding16/11/17
MDC Change of Director's Interest Notice16/11/17
MDC Appendix 3B16/11/17
MDC Results of Meeting10/11/17
MDC AGM Presentation 201710/11/17
MDC Appendix 4C - quarterlyPRICE SENSITIVE31/10/17
MDC MDC Completes First Medical Cannabis Oil (CBD/THC) ShipmentPRICE SENSITIVE24/10/17
MDC Notice of Annual General Meeting/Proxy Form09/10/17
MDC Medlab's Anti-Depression Product Granted 20 Year AU PatentPRICE SENSITIVE18/09/17
MDC Corporate Governance Statement 201731/08/17
MDC Appendix 4G31/08/17
MDC Annual Report to shareholders31/08/17
MDC Appendix 4EPRICE SENSITIVE31/08/17
MDC Appendix 4C - quarterlyPRICE SENSITIVE31/07/17
MDC Appendix 3B - Shares out of Escrow21/07/17
MDC Medlab and Heritage Brands Join Forces to Market ProductsPRICE SENSITIVE13/07/17
MDC Release of Shares and Options from Escrow29/06/17
MDC Medlab Granted Ethics Approval for Two Cannabis TrialsPRICE SENSITIVE19/06/17
MDC Corporate Governance Statement16/05/17
MDC Response to ASX QueryPRICE SENSITIVE05/05/17
MDC Appendix 4C - quarterlyPRICE SENSITIVE28/04/17
MDC Letter to Shareholders10/04/17
MDC Investor Presentation30/03/17
MDC MEDLAB GRANTED ETHICS APPROVAL FOR PHASE 2A DEPRESSION STUDYPRICE SENSITIVE27/03/17
MDC Medlab Signs Agreement to Start Comparison Study for StatinsPRICE SENSITIVE06/03/17
MDC December 2016 Financial Report28/02/17
MDC Shareholder Letter28/02/17
MDC Appendix 4DPRICE SENSITIVE28/02/17
MDC Government Easing of Cannabis Supply as Medlab Trial NearsPRICE SENSITIVE22/02/17
MDC Appendix 4C - quarterlyPRICE SENSITIVE31/01/17
MDC Breakthrough for Medlab - TGA Grants Licence for CannabisPRICE SENSITIVE10/11/16
MDC Media Release - Medlab Prepares to Start Cannabis TrialPRICE SENSITIVE07/11/16
MDC Results of Meeting04/11/16
MDC AGM 2016 - Presentation04/11/16
MDC Appendix 4C - quarterly-MDC.AX PRICE SENSITIVE31/10/16
MDC Notice of Annual General Meeting/Proxy Form-MDC.AX 05/10/16
MDC Change of Director's Interest Notice-MDC.AX 02/09/16
MDC Annual Report to shareholders-MDC.AX 31/08/16
MDC Appendix 4G-MDC.AX 31/08/16
MDC Preliminary Final Report-MDC.AX PRICE SENSITIVE31/08/16
MDC Rights Issue - Issue of Shortfall Shares-MDC.AX 30/08/16
MDC Medlab Heading to Phase 2A with Anti-Depression Therapy-MDC.AX PRICE SENSITIVE30/08/16
MDC Medlab & Aphria Complete Cannabis Supply Agreement-MDC.AX PRICE SENSITIVE22/08/16
MDC Change of Director's Interest Notice x 2-MDC.AX 17/08/16
MDC Change in substantial holding-MDC.AX 17/08/16
MDC Top 20 security holders - Updated-MDC.AX 16/08/16
MDC NanaBis Update
14/03/19PRICE SENSITIVE
MDC Cleansing Statement & Appendix 3B
08/03/19
MDC S&P DJI Announces March 2019 Quarterly Rebalance
08/03/19PRICE SENSITIVE
MDC MDC Executes HoA for NanaBis with Pharmascience Inc
05/03/19PRICE SENSITIVE
MDC Half Year Accounts
22/02/19
MDC Appendix 4D
22/02/19PRICE SENSITIVE
MDC MDC's Depression Trial Expands
14/02/19PRICE SENSITIVE
MDC Appendix 4C - quarterly
30/01/19PRICE SENSITIVE
MDC Medlab to Expand Nutraceutical Range into 2,100 Pharmacies
30/01/19PRICE SENSITIVE
MDC MDC Receives formal SME Qualification from EMA
17/01/19PRICE SENSITIVE
MDC NanoStat Demonstrates Improvement When Compared to Oral Drug
09/01/19PRICE SENSITIVE
MDC Medlab - Open Day
05/12/18
MDC Medlab Expands into Europe
04/12/18PRICE SENSITIVE
MDC Change in substantial holding
05/11/18
MDC Change in substantial holding
30/10/18
MDC Successful Completion of Stage 1 of NanaBis Trial
30/10/18PRICE SENSITIVE
MDC Results of Meeting
26/10/18
MDC Appendix 4C - quarterly
26/10/18PRICE SENSITIVE
MDC AGM Presentation 2018
26/10/18
MDC Notice of Annual General Meeting/Proxy Form
24/09/18
MDC Medlab Granted a Licence to Export Cannabis
11/09/18PRICE SENSITIVE
MDC Independent Research Validates Science around NanoCelle
04/09/18PRICE SENSITIVE
MDC Corporate Governance Statement 2018
31/08/18
MDC Appendix 4G
31/08/18
MDC Annual Report to shareholders
31/08/18
MDC Preliminary Final Report
31/08/18PRICE SENSITIVE
MDC Medlab Expands in Significant Area of Oncology with Trial
27/08/18PRICE SENSITIVE
MDC Change in substantial holding
17/08/18
MDC Appendix 4C - quarterly
31/07/18PRICE SENSITIVE
MDC Aphria Completes Largest Export Shipment to Date to Medlab
27/07/18PRICE SENSITIVE download Created with Sketch. 817.9KB
MDC Recruitment Begins - Phase 2A Trial for Depression Medicine
25/07/18PRICE SENSITIVE download Created with Sketch. 249.68KB
MDC Pain Trial on Schedule and Initial Doctor Feedback Positive
04/07/18PRICE SENSITIVE download Created with Sketch. 996.81KB
MDC MDC Cannabis Shipment Complated and Trial Commencement
15/05/18PRICE SENSITIVE
MDC Appendix 3Y
01/05/18
MDC Appendix 4C - quarterly
30/04/18PRICE SENSITIVE
MDC Letter to Shareholders
23/04/18
MDC Ceasing to be a substantial holder from MUFG
04/04/18
MDC Ceasing to be a substantial holder from MS
04/04/18
MDC Becoming a substantial holder from MUFG
29/03/18
MDC Becoming a substantial holder from MS
28/03/18
MDC S&P DJ Indices Announces March Quarterly Rebalance
09/03/18PRICE SENSITIVE
MDC Medlab's Progress to Date on Cannabis Spray (NanaBis)
02/03/18PRICE SENSITIVE
MDC Appendix 4D
28/02/18PRICE SENSITIVE
MDC Half Year Accounts
28/02/18
MDC Change in substantial holding
05/02/18
MDC Change in substantial holding
05/02/18
MDC Change in substantial holding
05/02/18
MDC Appendix 3B and Notice under Section 708(5)(e)
01/02/18
MDC Medlab Permitted to Sell or Supply Cannabis in QLD and ACT
01/02/18PRICE SENSITIVE
MDC Appendix 4C - quarterly
31/01/18PRICE SENSITIVE
MDC Successful Completion of a Heavily Over-Subscribed Placement
25/01/18PRICE SENSITIVE
MDC Trading Halt
23/01/18PRICE SENSITIVE
MDC Medlab Granted Licences-Sell or Supply Cannabis in Australia
10/01/18PRICE SENSITIVE
MDC MDC's Cannabis (CBD/THC) Product expected Late Feb 18
23/11/17PRICE SENSITIVE
MDC Change in substantial holding
16/11/17
MDC Change of Director's Interest Notice
16/11/17
MDC Appendix 3B
16/11/17
MDC Results of Meeting
10/11/17
MDC AGM Presentation 2017
10/11/17
MDC Appendix 4C - quarterly
31/10/17PRICE SENSITIVE
MDC MDC Completes First Medical Cannabis Oil (CBD/THC) Shipment
24/10/17PRICE SENSITIVE
MDC Notice of Annual General Meeting/Proxy Form
09/10/17
MDC Medlab's Anti-Depression Product Granted 20 Year AU Patent
18/09/17PRICE SENSITIVE
MDC Corporate Governance Statement 2017
31/08/17
MDC Appendix 4G
31/08/17
MDC Annual Report to shareholders
31/08/17
MDC Appendix 4E
31/08/17PRICE SENSITIVE
MDC Appendix 4C - quarterly
31/07/17PRICE SENSITIVE
MDC Appendix 3B - Shares out of Escrow
21/07/17
MDC Medlab and Heritage Brands Join Forces to Market Products
13/07/17PRICE SENSITIVE
MDC Release of Shares and Options from Escrow
29/06/17
MDC Medlab Granted Ethics Approval for Two Cannabis Trials
19/06/17PRICE SENSITIVE
MDC Corporate Governance Statement
16/05/17
MDC Response to ASX Query
05/05/17PRICE SENSITIVE
MDC Appendix 4C - quarterly
28/04/17PRICE SENSITIVE
MDC Letter to Shareholders
10/04/17
MDC Investor Presentation
30/03/17
MDC MEDLAB GRANTED ETHICS APPROVAL FOR PHASE 2A DEPRESSION STUDY
27/03/17PRICE SENSITIVE
MDC Medlab Signs Agreement to Start Comparison Study for Statins
06/03/17PRICE SENSITIVE
MDC December 2016 Financial Report
28/02/17
MDC Shareholder Letter
28/02/17
MDC Appendix 4D
28/02/17PRICE SENSITIVE
MDC Government Easing of Cannabis Supply as Medlab Trial Nears
22/02/17PRICE SENSITIVE
MDC Appendix 4C - quarterly
31/01/17PRICE SENSITIVE
MDC Breakthrough for Medlab - TGA Grants Licence for Cannabis
10/11/16PRICE SENSITIVE
MDC Media Release - Medlab Prepares to Start Cannabis Trial
07/11/16PRICE SENSITIVE
MDC Results of Meeting
04/11/16
MDC AGM 2016 - Presentation
04/11/16
MDC Appendix 4C - quarterly-MDC.AX
31/10/16PRICE SENSITIVE
MDC Notice of Annual General Meeting/Proxy Form-MDC.AX
05/10/16
MDC Change of Director's Interest Notice-MDC.AX
02/09/16
MDC Annual Report to shareholders-MDC.AX
31/08/16
MDC Appendix 4G-MDC.AX
31/08/16
MDC Preliminary Final Report-MDC.AX
31/08/16PRICE SENSITIVE
MDC Rights Issue - Issue of Shortfall Shares-MDC.AX
30/08/16
MDC Medlab Heading to Phase 2A with Anti-Depression Therapy-MDC.AX
30/08/16PRICE SENSITIVE
MDC Medlab & Aphria Complete Cannabis Supply Agreement-MDC.AX
22/08/16PRICE SENSITIVE
MDC Change of Director's Interest Notice x 2-MDC.AX
17/08/16
MDC Change in substantial holding-MDC.AX
17/08/16
MDC Top 20 security holders - Updated-MDC.AX
16/08/16
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
$6.60 		Change
0.000(0.00%) 		Mkt cap ! $15.07M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0
MDC (ASX) Chart

Top Stories

iTech inks deal with Chilean lithium giant to progress Reynolds Range

iTech Minerals Ltd has signed a deal which will allow for the development of its Reynolds Range lithium project
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
HotCopper users react as Pancontinental Energy's trading halt lift reveals little Pancontinental has lifted a trading halt to reveal its hotly awaited potential deal with Woodside is...still just potential.
IP anomaly thrills Cannidah with project extension hopes in QLD Cannidah Resources has carried out geophysical work at its flagship project in Queensland which highlighted an IP anomaly.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.